Serious hypersensitivity reactions (including anaphylaxis) have been reported following anifrolumab administration.

The efficacy of anifrolumab has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Use of anifrolumab is not recommended in these situations.